Match!
José L. Pablos
Complutense University of Madrid
PathologyImmunologyRheumatoid arthritisMedicineBiology
155Publications
37H-index
3,998Citations
What is this?
Publications 159
Newest
#2Eliseo AlbertH-Index: 5
Last. José L. Pablos (Complutense University of Madrid)H-Index: 37
view all 8 authors...
Abstract Objective Torque teno virus (TTV) is a highly prevalent non-pathogenic anellovirus whose plasma levels may be a biomarker of immunosuppression. The aim of this study was to assess whether specific immune-targeting with different biologic drugs may differentially modulate TTV viremia in arthritis patients. Methods TTV DNA load was quantified by PCR in a cross-sectional sample of 79 patients with chronic arthritis on biologic therapy (abatacept, infliximab, rituximab or tocilizumab), 31 p...
Source
#1José L. PablosH-Index: 37
#2Juan Ángel Jover (Hospital Clínico San Carlos)H-Index: 17
Last. Luis LizánH-Index: 13
view all 8 authors...
Objectives The aim of this study was to develop and assess the effectiveness of a patient decision aid (PDA) to support treatment decision making in Spanish patients with moderate-to-severe rheumatoid arthritis (RA) who fail to achieve the therapeutic goal with the current disease-modifying antirheumatic treatment strategy.
Source
#1Raquel Toribio-Fernandez (Centro Nacional de Investigaciones Cardiovasculares)H-Index: 1
view all 11 authors...
Source
#1José M. Ruiz de Morales (University of León)H-Index: 7
#2Lluís Puig (Autonomous University of Barcelona)H-Index: 38
Last. Miguel A. Gonz (UC: University of Cantabria)H-Index: 73
view all 16 authors...
Abstract Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. In this context, the present review in which a panel of 13 experts in immunology, dermatology, rheumatology, neurology, hematology, infectious diseases, hepatology, cardiology, ophthalmology and oncology have been involved, puts in common the mechanisms through which IL-17 is considered a...
1 CitationsSource
#1Manuel J. Del Rey (Grupo México)H-Index: 10
#2Alvaro Valin (Grupo México)H-Index: 2
Last. José L. Pablos (Complutense University of Madrid)H-Index: 37
view all 10 authors...
Background Accumulation of senescent cells has been associated with pro-inflammatory effects with deleterious consequences in different human diseases. The purpose of this study was to analyze cell senescence in human synovial tissues (ST), and its impact on the pro-inflammatory function of synovial fibroblasts (SF).
1 CitationsSource
#1C Peral (Pfizer)H-Index: 3
#2Alejandro BalsaH-Index: 41
Last. María Montoro (Pfizer)H-Index: 4
view all 11 authors...
Background: The availability of oral janus kinase inhibitors, as tofacitinib, has extended the treatment pathways for management of patients with rheumatoid arthritis (RA) Objectives: To assess the cost-effectiveness of tofacitinib as second-line treatment compared to treatment sequences containing standard biological-therapies in patients with moderate to severe RA after failure to disease-modifying antirheumatic drugs (DMARDs) from the Spanish National Health System perspective. Methods: A pat...
Source
#1Stanley N. CohenH-Index: 114
#2José L. PablosH-Index: 37
Last. Eswar Krishnan (Amgen)H-Index: 1
view all 8 authors...
ABP 501 was evaluated in a phase 3 single-arm, open-label extension (OLE) study to collect additional safety and efficacy data in patients with rheumatoid arthritis (RA). Subjects completing the final visit in the parent phase 3 randomized, double-blind, controlled equivalence study comparing the efficacy and safety of the biosimilar ABP 501 with adalimumab reference product (RP) were enrolled in this open-label extension (OLE) study. All subjects received 40 mg ABP 501 every other week for 68 w...
4 CitationsSource
3 Citations
#1C PeralH-Index: 3
#2F. NavarroH-Index: 14
view all 11 authors...
Source
12345678910